Skip to content

Platform
- Overview
- Publications
Pipeline
Patients
About Us
Partnerships
News
Careers

Platform
- Overview
- Publications
Pipeline
Patients
About Us
Partnerships
News
Careers

COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer

By lsc-webmaster / February 28, 2022

COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis

COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model

Skokie, Illinois
info@courpharma.com

Science

Platform
Publications
Pipeline

Patients

Overview
Patient Resources
CNP-103 Clinical Trial in Type 1 Diabetes
CNP-106 Clinical Trial in Myasthenia Gravis

Company

About Us
Partnerships
News
Careers

Privacy Policy
Terms of use
Accessibility
Expanded Access Policy
Cookie policy

© 2025 COUR Pharmaceuticals

Scroll to Top